Navigation Links
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
Date:12/2/2008

iming and scope of clinical trials of NGX267. Such statements are subject to numerous risks, and uncertainties that may cause actual events or results to differ materially from the company's current expectations. Statements regarding TorreyPines Therapeutics' product candidates are subject to risks and uncertainties regarding development, regulatory approval and commercialization, including whether the results of completed trials of NGX267 are predictive of results in subsequent trials of such product candidate; whether further testing of NGX267 will result in data sufficient to support regulatory approval; whether TorreyPines' cash resources will be sufficient to fund operations as planned, whether the company will be able to develop and obtain regulatory approval of its product candidates for treatment of multiple diseases and disorders; whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its product candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its product candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its product candidates will support a filing for marketing approval, will be approved by applicable regulatory authorities, or if approved, will prove competitive in the market; and whether the necessary financing to support its product development programs will be available. Actual results may differ materially from the above forward-looking statements due to a number of other important factors. These and other risks which may impact management's expectations are described in greater detail in the TorreyPines Therapeutics ann
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
2. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
3. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
5. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
6. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
7. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Calif. , Nov. 21, 2014 In ... and Performance Scrubs carried out a new product development ... industry,s very first "limited edition" lab coat , ... female professors of surgery in the world. The new ... its unisex predecessors, with a sleek envelope collar, vertical ...
(Date:11/21/2014)... Nov. 21, 2014  Heated dialogue in recent months ... from cancer treatments to Gilead,s new hepatitis C drug ... the world questioning what it means to put a ... And while drug pricing is one of ... from both a general business and ethical standpoint – ...
(Date:11/21/2014)... 2014 Clementia Pharmaceuticals, ... dass die Europäische Arzneimittel-Agentur (European Medicines ... Orphan-Medizinprodukt an Palovarotene vergeben hat, den ... von Fibrodysplasia ossificans progressiva (FOP). FOP ... Krankheit, die von schmerzhaften, wiederkehrenden Episoden ...
Breaking Medicine Technology:Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
(Date:11/21/2014)... Angeles, CA (PRWEB) November 21, 2014 ... reference for the dental practice. It includes everything needed ... . , Procedure Coding with CDT , CDT 2015 ... provided from January 1, 2014 - December 31, 2014. ... report procedures and services on dental claims. There are ...
(Date:11/21/2014)... Even with years of experience under his belt, ... for growth, participating in two recent events for his State ... a networking event with the leaders of State Farm and ... latest and greatest in insurance news and products for his ... team (Stacy, Anthony, Reina and Jacob) as exhibitors at the ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 CARE Surrogacy ... its intended parents — and at the same time enhancing ... sense of optimism for future parents across the globe, the ... , Prospective parents today are zoning in on the skyrocketing ... the encumbering costs, are individuals over-stressing clinical success rates ...
(Date:11/21/2014)... 21, 2014 According to a National ... June 11th, 2014, the inflating system found in certain ... airbag inflates. The force of inflation may cause the ... metal shards may pierce the airbag’s fabric and potentially ... , According to a Bloomberg Business Week article ...
(Date:11/21/2014)... 2014 Nature’s Sleep is excited to announce the ... contest calls for the creation of any type of art — ... encompasses sleep, a bed or a mattress. , “We had ... Vice President of Marketing for Nature’s Sleep, “that we decided to ... than 10,000 creative entries from some very talented artists all the ...
Breaking Medicine News(10 mins):Health News:PMIC Announces CDT PLUS! 2015, the Ultimate Coding Reference for Dentists and Oral Surgeons 2Health News:Kirk Martin Insurance Agency Goes Local and National with State Farm 2Health News:CARE Surrogacy Center Reports on its Multiple Measures of Success 2Health News:CARE Surrogacy Center Reports on its Multiple Measures of Success 3Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 3Health News:Nature’s Sleep Kicks Off their 2nd Art Of Sleep Contest 2
... The chances of suffering a stroke are linked to the ... system, a new study from Karolinska Institutet shows. The researchers ... mobilise the body,s own defence against arteriosclerosis and stroke. ... Frostegrd, has previously demonstrated that high levels of a certain ...
... taking action, study finds , FRIDAY, Feb. 12 ... opening in Canada Friday seem more on the ball ... activity enables elite athletes to see and react to ... new study finds. , Researchers analyzed the reaction time ...
... successfully inserted to reopen clogged coronary artery , THURSDAY, ... was said to be "in good spirits" Thursday evening ... two stents inserted into a clogged heart artery. , ... 2004, had been complaining of chest pains. , "Today ...
... , ... in Twin Cities , ... February 12, 2010 -- Ecumen an innovative non-profit senior housing, services and ... on its second senior housing community in Apple Valley and will manage The Seasons at ...
... ... to an underage passenger hurt in a vehicle crash after he left a party. ... Providence, RI (PRWEB) February 12, ... the liability homeowners face when they allow underage drinking in their homes., , ,Details of ...
... , ... Qigong has been called the secret of youth and longevity, and in his latest book, ... Eastern movements can slow the ageing process down and promote youthful skin from the inside ... (PRWEB) February 12, ...
Cached Medicine News:Health News:Ex-President Clinton Said To Be Fine After Heart Procedure 2Health News:Ex-President Clinton Said To Be Fine After Heart Procedure 3Health News:Ecumen Building Senior Housing in Apple Valley, Minnesota and Will Manage New Maplewood, Minnesota Property 2Health News:Ecumen Building Senior Housing in Apple Valley, Minnesota and Will Manage New Maplewood, Minnesota Property 3Health News:Rhode Island Settlement Reflects Homeowner Liability for Serving Alcohol to Those Under 21, Says Providence Lawyer Mark Gemma 2Health News:New Book Reveals How Qigong Could Be The Eastern Answer To Botox 2
... designed with the safety and comfort of the ... (also called SF-6) leaded glass, the industry standard ... as set for optical clarity, visible light transmission, ... is protecting your eyes, it also helps you ...
Panoramic styling that contours closely to the face and brow. Saddle bridge fits average to fuller noses. Adjustable temple hinge adjusts up or down, longer or shorter. Soft cushion behind ear for co...
Qualcraft™ Radiation Protection Eyewear, Metal, Bifocal. Provides maximum comfort and eye protection! Plano (nonprescription). Black with bronze temple bar....
QualCraft™ Radiation-Reducing Eyewear is 50% lighter than other protective eyewear. Manufactured for the ultimate combination of comfort, function, and protection....
Medicine Products: